First Tracks Biotherapeutics (MEX:TRAX) Net Income: MXN-3,414.18 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TRAX First Tracks Biotherapeutics Inc MEX:TRAX
12 GF Score
Price MXN800.00
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Net Income?

First Tracks Biotherapeutics MEX:TRAX 12 Net Income is MXN-3,414.18 Mil as of Dec. 2024. GuruFocus rates MEX:TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. First Tracks Biotherapeutics's Net Income for the six months ended in Dec. 2024 was MXN-3,414.18 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-3,414.18 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. First Tracks Biotherapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was MXN-98.25.


First Tracks Biotherapeutics  (MEX:TRAX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

First Tracks Biotherapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


First Tracks Biotherapeutics Net Income Related Terms


First Tracks Biotherapeutics Net Income Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Net Income Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Net Income
-1,801.82 -3,414.18

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Net Income -1,801.82 -3,414.18
MEX:TRAX
12GF Score
First Tracks Biotherapeutics Inc MEX:TRAX
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

First Tracks Biotherapeutics's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-3414.182+0+0+0
=-3,414.18

First Tracks Biotherapeutics's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-3414.182+0+0+0
=-3,414.18

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-3,414.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of MXN-3,414.18 Mil mean?
First Tracks Biotherapeutics (MEX:TRAX) has a Net Income of MXN-3,414.18 Mil as of Dec. 2024. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Net Income too high?
First Tracks Biotherapeutics' current Net Income is MXN-3,414.18 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Net Income compare to AVLN and IMTX?
First Tracks Biotherapeutics' Net Income of MXN-3,414.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Net Income is MXN-3,414.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (MEX:TRAX) has a current Net Income of MXN-3,414.18 Mil. The current Net Income is MXN-3,414.18 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For First Tracks Biotherapeutics (MEX:TRAX), the current Net Income is MXN-3,414.18 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USAB43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for MEX:TRAX

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN800.00
Price